Press release - 07/12/2021 Moderate immune response is more effective against leukemia The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.https://www.gesundheitsindustrie-bw.de/en/article/press-release/moderate-immune-response-more-effective-against-leukemia
Press release - 07/12/2021 New approach developed to predict response of immunotherapies in lung cancer At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
Press release - 03/12/2021 ARDIA-Net preliminary results presented in the Kick-Off Conference of Interreg Alpine Space 2021-27 The Kick-Off Conference of the new Interreg Alpine Space programme, which gathered more than 300 attendees, was organized by the Joint Secretariat in Salzburg and held online due to the COVID-19 restrictions established by the Austrian Government days previous to the celebration. It consisted of a two half-day programme (22nd and 23rd of November) under the motto “Let’s change our altitude”.https://www.bio-pro.de/en/information/press-release/ardia-net-preliminary-results-presented-kick-conference-interreg-alpine-space-2021-27
Gene regulation as a starting point for cancer therapies - 02/12/2021 New investigation method for deciphering complex epigenetic networks The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.https://www.gesundheitsindustrie-bw.de/en/article/news/new-investigation-method-deciphering-complex-epigenetic-networks
Press release - 30/11/2021 A mould dominates the eukaryotic microbiota in Parkinson’s disease patients Parkinson's disease is characterised by a slow, progressive loss of nerve cells in certain brain areas. The disease is still incurable and the exact causes are unclear. The dopamine deficiency in the brain can only be controlled to some extent in the initial phase of the disease. Basic research is being conducted in an attempt to unravel the mystery of Parkinson's disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mould-dominates-eukaryotic-microbiota-parkinsons-disease-patients
Press release - 29/11/2021 Tracking down resistant cancer cells In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracking-down-resistant-cancer-cells
Laboratory automation - 29/11/2021 Reaching the goal quickly and efficiently with the help of artificial intelligence Medical research is slow, costly and time-consuming. The system developed by the start-up LABMaiTE could soon change that. With the help of artificial intelligence, it will be possible to automate laboratory experiments and collect and analyse data at the same time.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-goal-quickly-and-efficiently-help-artificial-intelligence
Further utilisation of plant residues - 25/11/2021 Novel fibre composite made from hop fermentation residues Biogas plants produce energy-rich gas by fermenting biomass. This process generates both liquid and solid fibrous and particulate fermentation residues. Researchers at the German Institutes of Textile and Fibre Research (DITF) have now managed to create a resistant and water-repellent fibre composite material from solid hop residues that can be used as a veneer to coat wood panels.https://www.biooekonomie-bw.de/en/articles/news/novel-fibre-composite-made-hop-fermentation-residues
Cluster of the future - 25/11/2021 nanodiagBW: using nanopores to create completely new diagnostic possibilities Modern medicine has a wide range of molecular diagnostics at hand. In the next decade, this will increasingly be supplemented by prognostic methods. The BMBF Cluster of the Future finalist, nanodiag BW, is developing prognostic methods to identify epigenetic factors for diseases through a new type of bioanalytics – single molecule analysis in nanopores – which would make it possible to take personalised prevention approaches.https://www.gesundheitsindustrie-bw.de/en/article/news/nanodiagbw-using-nanopores-create-completely-new-diagnostic-possibilities
Press release - 25/11/2021 Environmentally-friendly reforestation: Biodegradable tree covers made from renewable raw materials. In reforestation projects, the seedlings must be protected. So-called growth covers prevent game from feeding on the young plants and help to ensure that they are not prevented from growing by other plants. Previously used sheaths made of plastic and metal are often not removed in time and pollute the environment. The DITF have developed a biodegradable yarn for growth covers from renewable raw materials.https://www.biooekonomie-bw.de/en/articles/pm/environmentally-friendly-reforestation-biodegradable-tree-covers-made-renewable-raw-materials
Press release - 25/11/2021 New Collaborative Research Centre at Ulm University Focusing on the factors that influence human aging After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-collaborative-research-centre-ulm-university-focusing-factors-influence-human-aging
Press release - 23/11/2021 Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
Press release - 22/11/2021 Wound Lightness - Towards a novel material culture The Cluster of Excellence IntCDC of the University of Stuttgart presents the "Maison Fibre" at the International Architecture Exhibition Venice. The full-scale inhabitable installation is made from robotically produced, fibrous building elements.https://www.biooekonomie-bw.de/en/articles/pm/gewickelte-leichtigkeit-neue-materialkultur-der-architektur
Press release - 19/11/2021 Keep an eye on us! – Bacteria on slit lamps Furtwangen University publishes the world’s first molecular biological study on bacterial contamination of slit lamps. Slit lamps are among the most important tools used by ophthalmologists and opticians. They allow selected areas of the eye to be magnified and examined for diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/keep-eye-us-bacteria-slit-lamps
Funding Digital Europe Programme Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://www.gesundheitsindustrie-bw.de/en/database/funding/digital-europe-programme
Funding Digital Europe Programme Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://www.bio-pro.de/en/service/funding/digital-europe-programme
Funding Digital Europe Programme Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://www.biooekonomie-bw.de/en/databases/funding/digital-europe-programme
Press release - 18/11/2021 Overcoming resistance to treatment for breast, bowel, and pancreatic cancer As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
Press release - 18/11/2021 Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
Microfluidic systems - 18/11/2021 Dermagnostix develops molecular diagnostic tests for skin diseases Dermagnostix GmbH has developed a rapid test to differentiate between psoriasis and eczema. This test is currently undergoing preclinical testing, with market launch planned for 2023. The start-up is already working on two other dermatological tests. Centrifugal microfluidics is the name of the technology on which the tests are based.https://www.gesundheitsindustrie-bw.de/en/article/news/dermagnostix-develops-molecular-diagnostic-tests-skin-diseases
Dossier - 17/11/2021 Biorefinery: new paths to build our tomorrow Sustainability is in vogue. And it’s not a question of wanting to be sustainable, but having to be: as the latest report from the Intergovernmental Panel on Climate Change shows, protecting the climate and the environment calls for swift action. Biorefineries that use renewable raw materials and recycle industrial raw materials are playing an important role in the bioeconomy concepts of many countries - including the state of Baden-Württemberg.https://www.biooekonomie-bw.de/en/articles/dossiers/biorefinery-new-paths-build-our-tomorrow
Press release - 16/11/2021 Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cystic-fibrosis-copd-mucus-reprograms-immune-cells-and-promotes-airway-inflammation
Press release - 15/11/2021 Using T cell to target malignant brain tumors Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors